Pyxis Oncology to Participate in Two Upcoming Investor Conferences
Pyxis Oncology, Inc. (PYXS)
Company Research
Source: GlobeNewswire
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in fireside chats and members of management will participate in one-on-one meetings at the following two upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY, on September 6 at 12:20 PM Eastern Time H.C. Wainwright 26th Annual Global Investment Conference in New York, NY, on September 9 at 2:00 PM Eastern Ti A live webcast and replay of the presentations will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficien
Show less
Read more
Impact Snapshot
Event Time:
PYXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PYXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PYXS alerts
High impacting Pyxis Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
PYXS
News
- Pyxis Oncology, Inc. (NASDAQ: PYXS) had its price target raised by analysts at Royal Bank of Canada from $7.00 to $10.00. They now have an "outperform" rating on the stock.MarketBeat
- Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Pyxis Oncology, Inc. (NASDAQ: PYXS) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.MarketBeat
- Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data [Yahoo! Finance]Yahoo! Finance
- Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 DataGlobeNewswire
PYXS
Earnings
- 11/12/24 - Miss
PYXS
Sec Filings
- 11/20/24 - Form 8-K
- 11/12/24 - Form S-8
- 11/12/24 - Form SC
- PYXS's page on the SEC website